|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
FDA To Weigh Fate Of Bextra, Celebrex, Similar Drugs
10/19/2005 5:12:42 PM
When it debuted in 1999, Vioxx was hailed as a wonder drug, even though its advantage lay not in better pain relief but in fewer side effects.
Soon, the drug and others like it in the same class of cox-2 inhibitors became widely prescribed, particularly to arthritis sufferers, thanks to heavy advertising by manufacturers.
Now, the drugs face intense scrutiny over heart risks posed by the medicines. Starting Wednesday, a U.S. Food and Drug Administration (FDA) advisory panel will meet for three days to debate the future of the cox-2s and perhaps even their predecessors, the cox-1s.
At issue is the safety of the drugs. Although originally introduced as a better alternative to traditional nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and naproxen -- all of which increase the risk of gastrointestinal bleeding -- recent evidence suggests the cox-2s, as well as naproxen, may elevate the risk of heart attack and stroke.
|
|
|
|
|
|
|
|
|
|
|